Keywords: dupont, pitches, sustiva, heir, protease, inhibitors, new

DuPont Pitches Sustiva As Heir To Protease Inhibitors

Article | 09 July 1998

Print This

New clinical data presented at the 12th World Conference on AIDS inGeneva suggest that DuPont Merck's Sustiva (efavirenz) is a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in